Compare GENNEX LABORATORIES with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GENNEX LAB. vs AUROBINDO PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GENNEX LAB. AUROBINDO PHARMA GENNEX LAB./
AUROBINDO PHARMA
 
P/E (TTM) x 24.5 7.3 335.9% View Chart
P/BV x 3.2 1.8 184.7% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 GENNEX LAB.   AUROBINDO PHARMA
EQUITY SHARE DATA
    GENNEX LAB.
Mar-21
AUROBINDO PHARMA
Mar-21
GENNEX LAB./
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs61,023 0.6%   
Low Rs2333 0.5%   
Sales per share (Unadj.) Rs4.4422.8 1.0%  
Earnings per share (Unadj.) Rs0.392.0 0.3%  
Cash flow per share (Unadj.) Rs0.4110.0 0.4%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Avg Dividend yield %00.6 0.0%  
Book value per share (Unadj.) Rs3.1374.3 0.8%  
Shares outstanding (eoy) m126.50585.94 21.6%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x0.91.6 55.8%   
Avg P/E ratio x12.37.4 167.4%  
P/CF ratio (eoy) x10.16.2 164.3%  
Price / Book Value ratio x1.31.8 69.3%  
Dividend payout %04.3 0.0%   
Avg Mkt Cap Rs m498397,398 0.1%   
No. of employees `000NANA-   
Total wages/salary Rs m7235,350 0.2%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m556247,746 0.2%  
Other income Rs m53,809 0.1%   
Total revenues Rs m562251,555 0.2%   
Gross profit Rs m6281,480 0.1%  
Depreciation Rs m910,554 0.1%   
Interest Rs m7745 1.0%   
Profit before tax Rs m5173,990 0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1020,098 0.1%   
Profit after tax Rs m4053,892 0.1%  
Gross profit margin %11.132.9 33.7%  
Effective tax rate %20.227.2 74.5%   
Net profit margin %7.321.8 33.4%  
BALANCE SHEET DATA
Current assets Rs m377198,235 0.2%   
Current liabilities Rs m190106,652 0.2%   
Net working cap to sales %33.537.0 90.6%  
Current ratio x2.01.9 106.4%  
Inventory Days Days4719 242.9%  
Debtors Days Days58,680,59652 113,693,020.1%  
Net fixed assets Rs m212135,778 0.2%   
Share capital Rs m127586 21.6%   
"Free" reserves Rs m271218,713 0.1%   
Net worth Rs m397219,299 0.2%   
Long term debt Rs m01,684 0.0%   
Total assets Rs m589334,013 0.2%  
Interest coverage x7.8100.3 7.8%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.90.7 127.4%   
Return on assets %8.116.4 49.6%  
Return on equity %10.224.6 41.4%  
Return on capital %14.633.8 43.2%  
Exports to sales %41.253.8 76.6%   
Imports to sales %4.416.4 26.6%   
Exports (fob) Rs m229133,248 0.2%   
Imports (cif) Rs m2440,615 0.1%   
Fx inflow Rs m229133,248 0.2%   
Fx outflow Rs m2944,946 0.1%   
Net fx Rs m20188,302 0.2%   
CASH FLOW
From Operations Rs m-1433,289 -0.0%  
From Investments Rs mNA5,987 -0.0%  
From Financial Activity Rs m16-13,648 -0.1%  
Net Cashflow Rs m225,831 0.0%  

Share Holding

Indian Promoters % 22.1 48.8 45.2%  
Foreign collaborators % 0.0 3.1 -  
Indian inst/Mut Fund % 0.0 37.9 -  
FIIs % 0.0 21.4 -  
ADR/GDR % 0.0 0.0 -  
Free float % 78.0 48.2 161.8%  
Shareholders   50,052 341,568 14.7%  
Pledged promoter(s) holding % 8.1 24.4 33.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GENNEX LAB. With:   SUN PHARMA    LUPIN    CIPLA    DR. REDDYS LAB    CADILA HEALTHCARE    



Today's Market

Sensex Sheds 427 Points, Nifty Ends Near 17,600; Bajaj Finserv, Tata Steel & Tech Mahindra Top Losers(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended on a weak note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY22); Net Profit Down 2.0% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (down 2.0% YoY). Sales on the other hand came in at Rs 57 bn (down 3.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

Here's an analysis of the annual report of AUROBINDO PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

Aurobindo Pharma Rallies on Sale of Injectables Unit to Subsidiary (Views On News)

Jul 2, 2021

Here's why the company sold its business unit to Eugia Pharma Specialities.

Aurobindo Pharma's Stock Falls After Profits Decline 7% (Views On News)

Jun 1, 2021

Aurobindo Pharma shares fell nearly 4% after quarterly earnings disappoint.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

More Views on News

Most Popular

10 Indian Companies with the Fastest Growth in Dividend Payouts...(Views On News)

Jan 10, 2022

These companies have been consistently paying higher dividends for several years.

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain(Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

Time to Buy Energy Stocks(Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GENNEX LAB. SHARE PRICE


Jan 21, 2022 (Close)

TRACK GENNEX LAB.

  • Track your investment in GENNEX LAB. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GENNEX LAB. 8-QTR ANALYSIS

COMPARE GENNEX LAB. WITH

MARKET STATS